Strategy execs advise Big Pharma

How might drugmakers navigate the rocky waters of generic competition, cautious regulators, safety scandals, globalization, and so on? Seek help with the itinerary from an expert, perhaps. At least six top U.S. drugmakers have done this, putting strategy gurus in top offices: Eli Lilly and Wyeth did so over a year ago; Johnson & Johnson, Bristol-Myers Squibb, Pfizer and Merck brought in their strategy types within the past six months. These folks have been charged with everything from charting new business opportunities to supervising cost-cutting plans to getting company divisions to parley.

The Wall Street Journal takes a look at this trend today. So far, it's too early to know how effective the strategy execs have been so far. Plus, the companies aren't exactly fulsome in their descriptions of what these folks are doing. But if they truly are looking with objective eyes at the pharma industry, they could nudge drugmakers to big changes in their business models. We'll see.

- check out the WSJ article
- see the WSJ Health Blog item

Related Articles:
Can Big Pharma effectively develop new drugs? Pharma report
Is pharma addicted to blockbusters? Report
Say goodbye to Big Pharma's gilded age. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.